ReviewCurrent hypertension reports2010
Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis.
Review in Current hypertension reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Transplantation of human endometrial perivascular stem cells with hydroxy saffron yellow A promotes uterine repair in rats.Stem cell research & therapy · 2024Article
- Epithelial cell invasion byVirulence · 2023Article
- Hypoxia pretreatment improves the therapeutic potential of bone marrow mesenchymal stem cells in hindlimb ischemia via upregulation of NRG-1.Cell and tissue research · 2022Article
- Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors.Experimental and therapeutic medicine · 2018Article
- The roles of neuregulin-1 in cardiac development, homeostasis, and disease.Biomarker insights · 2015Review
- Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.Toxicological sciences : an official journal of the Society of Toxicology · 2014Article
- Cardiac side effects of anticancer treatments: new mechanistic insights.Current heart failure reports · 2012Review
- The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation.American journal of physiology. Heart and circulatory physiology · 2012Review
- Cardiotoxicity of molecularly targeted agents.Current cardiology reviews · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cytostatic drugs were developed to target specific molecular pathways shown to drive tumor growth. Although this approach has been very successful in treating cancers, its use is often hindered by off-target toxic effects. An example of this is trastuzumab, which targets the erbB2 kinase receptor. This drug successfully decreases tumor growth but adversely affects cardiac function. This observation led to important studies elucidating the importance of the erbB pathway in cardioprotection and angiogenesis. This review addresses the problem of off-target effects of cytostatic drugs (specifically trastuzumab) and their effect on cardiac function, summarizes the neuregulin-1 (NRG)/erbB signaling pathway, and discusses its importance in cardiac myocytes. It also highlights important findings showing the role of NRG/erbB signaling in microvascular preservation and angiogenesis, with a brief discussion of preclinical and clinical data regarding treatment of cardiovascular disease with NRG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.